[17] Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection.

[17] In 2022, it was the 76th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

[19][20] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.

[22] Insulin aspart is indicated to improve glycemic control in people with diabetes.

The side effects that are commonly associated with insulin therapy include: allergic reactions, injection site irritation, rashes, and hypoglycemia.

[30][15] NovoRapid is produced in Saccharomyces cerevisiae by recombinant DNA technology.

[11] A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.

[37] In February 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Truvelog Mix 30, intended for the treatment of diabetes.

[41] In type 1 diabetes it appears to result in slightly better blood sugar control.